| Lloyd A. Rowland |
Lloyd A. Rowland is currently a Trustee at Rady Children's Hospital Foundation-San Diego and serves as Secretary, Compliance Officer & General Counsel at CytomX Therapeutics, Inc. Previously, he held positions as Secretary, Vice President & General Counsel at Alliance Pharmaceutical Corp. from 1993 to 2001, Chief Compliance Officer, VP & General Counsel at Amylin Pharmaceuticals, Inc. from 2001 to 2013, Secretary, Chief Compliance Officer & Senior VP at Xencor, Inc. from 2014 to 2017, and VP, Senior Counsellor-Finance & Securities at Imperial Savings Association (Amarillo, Texas) in 2009. He obtained his undergraduate degree from Southern Methodist University and his graduate degree from Emory University School of Law. |
| Jeffrey Landau |
Jeffrey Landau's career history includes current and former positions as well as his education background. Currently, he is the Chief Business Officer, Senior VP & Head-Strategy at CytomX Therapeutics, Inc. Prior to his current role, he held the position of Vice President-Business Development at Catalyst Biosciences, Inc. from 2016 to 2021. Before that, he worked as the Director-Corporate Development & Marketing at Threshold Pharmaceuticals, Inc. Mr. Landau completed his undergraduate degree at Virginia Polytechnic Institute & State University and holds an MBA from Stanford Graduate School of Business. |
| Yu Waye Chu |
Yu Waye Chu is currently the Chief Medical Officer at CytomX Therapeutics, Inc. Prior to this, he held the position of Chief Medical Officer at Fate Therapeutics, Inc. from 2019 to 2023. Before that, he worked at Genentech, Inc. as a Group Director-Medical from 2009 to 2019. Dr. Chu completed his undergraduate degree at Princeton University and obtained a doctorate from the University of Rochester School of Medicine & Dentistry. |
| Marcia P. Belvin |
Marcia P. Belvin is currently the Chief Scientific Officer & Senior Vice President at CytomX Therapeutics, Inc. She has a doctorate degree from the University of California, Berkeley and an undergraduate degree from Harvard University. |
| Chris Ogden |
Chris Ogden is currently the Chief Financial & Accounting Officer at CytomX Therapeutics, Inc. He previously worked as the Chief Financial Officer-Diabetes Division at Eli Lilly & Co. and as the Chief Financial Officer & Treasurer at Lilly del Caribe, Inc. Mr. Ogden completed his undergraduate degree at Wabash College and holds an MBA from Harvard Business School. |
| Sean A. McCarthy |
Sean A. McCarthy is currently the Chairman & Chief Executive Officer at CytomX Therapeutics Holdings LLC and the Chairman, President & Chief Executive Officer at CytomX Therapeutics, Inc. He is also a Director at the California Biomedical Innovation Alliance, OncoResponse, Inc., and the California Life Sciences Association. Previously, Dr. McCarthy held positions as the Associate Director-Program Management at Millennium Pharmaceuticals, Inc., Director at TYRX, Inc., Vice President-Business Development at SGX Pharmaceuticals, Inc., and Transactional Partner at Pappas Capital LLC. Dr. McCarthy received his undergraduate degree from King's College London, his doctorate from St. John's College, and his MBA from the Rady School of Management at UC San Diego. |
| Su Zhen |
Su Zhen is currently the Chief Executive Officer & Director at Marengo Therapeutics, Inc., an Independent Director at Karyopharm Therapeutics, Inc., and an Independent Director at CytomX Therapeutics, Inc. Previously, Dr. Zhen held the position of SVP & Global Head-Oncology Business at Merck KGaA from 2019 to 2021 and Chief Medical Officer at EMD Serono, Inc. from 2017 to 2019. Dr. Zhen holds an MBA from the University of Toronto and a doctorate from Dresden University of Technology. |
| James R. Meyers |
James R. Meyers is currently the President & Chief Executive Officer at IntraBio, Inc. He is also an Independent Director at Sangamo Therapeutics, Inc., a Director at the Biotechnology Innovation Organization, an Independent Director at Arbutus Biopharma Corp., a Director at Pulmocide Ltd., an Independent Director at CytomX Therapeutics, Inc., and a Director at the California Biomedical Innovation Alliance. Previously, he worked at Gilead Sciences, Inc. as the Executive VP-Worldwide Commercial Operations from 2016 to 2018. Mr. Meyers completed his undergraduate degree at Boston College. |
| Elaine V. Jones |
Elaine V. Jones is currently the Chairman at Gritstone bio, Inc. and the Director at HBM Healthcare Investments AG. She also holds positions as a Director at Novartis Venture Fund, Autifony Therapeutics Ltd., MISSION Therapeutics Ltd., CytomX Therapeutics, Inc., NextCure, Inc., Nimbus Apollo, Inc., Mironid Ltd., STORM Therapeutics Ltd., Jnana Therapeutics, Inc., Myeloid Therapeutics, Inc., and Ibere Pharmaceuticals. Dr. Jones is a Trustee at Juniata College and an Advisor at Ben Franklin Technology Partners. In the past, she served as an Independent Director at Mersana Therapeutics, Inc. and Flexion Therapeutics, Inc. She also held positions at various other companies including Aquinox Pharmaceuticals, Inc., Mirna Therapeutics, Inc., and Pfizer Ventures LLC. Dr. Jones received her undergraduate degree from Juniata College and her doctorate from the University of Pittsburgh School of Medicine. |
| Mani Mohindru |
Mani Mohindru founded Immtox LLC in 2012. Dr. Mohindru also currently works at Cardiff Oncology, Inc., as Independent Director from 2021 and CytomX Therapeutics, Inc., as Independent Director from 2020. Dr. Mohindru also formerly worked at CereXis, Inc., as Chief Executive Officer from 2019 to 2020, Novasenta, Inc., as Chief Executive Officer & Director from 2021 to 2024, Capstone Investments, as Managing Director, SAB Sciences, Inc., as Director from 2020 to 2021, Credit Suisse Securities (USA) LLC (Broker), as Research Analyst, Curis, Inc., as Chief Strategy Officer from 2016 to 2017, UBS Securities LLC, as Research Analyst, CARA Therapeutics, Inc., as Chief Financial & Strategy Officer from 2017 to 2019, ThinkEquity LLC, as Analyst, and Axon Healthcare Ltd., as Partner from 2009 to 2011. Dr. Mohindru received her doctorate degree in 2003 from Northwestern University and undergraduate degree and graduate degree from All India Institute of Medical Sciences. |
| Alan Ashworth |
Alan Ashworth is the founder of Tango Therapeutics Sub, Inc. (founded in 2017) and Tango Therapeutics, Inc. (founded in 2017). He currently holds the position of Independent Director at CytomX Therapeutics, Inc. since 2021. He is also a Member of the Academy of Medical Sciences, the European Molecular Biology Organization, and the UCSF Helen Diller Family Comprehensive Cancer Center. Additionally, he serves as an Advisor at Phoenix Molecular Designs Ltd., Ambagon Therapeutics, Inc., and Catalio Capital Management LP. Dr. Ashworth previously held the position of Chief Executive Officer at The Institute of Cancer Research and Director at the American Association for Cancer Research and Breakthrough Breast Cancer. He completed his undergraduate studies at Imperial College London and obtained a doctorate degree from University College London. |
| Matthew P. Young |
Matthew P. Young is currently a Managing Director at Longitude Capital Management Co LLC since 2022. He is also a Lead Independent Director at CytomX Therapeutics, Inc. since 2015 and a Director at Orsobio, Inc. Previously, Mr. Young held the position of Managing Director at Lehman Brothers, Inc. from 2003 to 2007. He was also an Independent Director at PRA Health Sciences, Inc. from 2015 to 2021. Additionally, he served as Managing Director at Citigroup Global Markets, Inc. from 2007 to 2008 and as Managing Director-Global Healthcare at Barclays Capital, Inc. from 2009 to 2013. Mr. Young was a Director at Merrill Lynch & Co., Inc. from 1994 to 2003. He also served as Chief Financial Officer & Executive Vice President at Jazz Pharmaceuticals Plc from 2013 to 2019 and as Chief Operating Officer & Chief Financial Officer at GRAIL, Inc. from 2019 to 2021. Mr. Young obtained his undergraduate degree in 1991 and an MBA from The Wharton School of the University of Pennsylvania in 1992. |
| Halley E. Gilbert |
Halley E. Gilbert currently works at Greater Boston Legal Services, Inc., as Director, CytomX Therapeutics, Inc., as Independent Director from 2020, Vaxcyte, Inc., as Independent Director from 2020, Allergy Amulet, Inc., as Director, Arcutis Biotherapeutics, Inc., as Independent Director from 2020, Massachusetts Bar Association, as Member, and Cargo Therapeutics, Inc., as Chief Legal Officer from 2023. Ms. Gilbert also formerly worked at Achaogen, Inc., as Independent Director from 2017 to 2019, Dermira, Inc., as Director from 2019 to 2020, Cubist Pharmaceuticals LLC, as VP, Deputy General Counsel & Assistant Secretary from 2002 to 2008, NeoGenomics, Inc., as Chief Legal Officer, Genzyme Corp., as Corporate Counsel from 1999 to 2002, Ironwood Pharmaceuticals, Inc., as Secretary & Chief Administrative Officer from 2019 to 2020, Skadden, Arps, Slate, Meagher & Flom LLP, as Associate from 1995 to 1998, and Invivyd, Inc., as Chief Operating & Business Officer from 2020 to 2021. Ms. Gilbert received her undergraduate degree from Tufts University and graduate degree from Northwestern University School of Law. |
